Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Clinicaltrials.gov ID
NCT04644068
Status
Recruiting
Study Type
Interventional, Phase 1/2
Sponsor
AstraZeneca
Start Date
November 12, 2020
Anticipated End Date
December 15, 2026
Study Contact
Name: AstraZeneca Clinical Study Information Center
Phone Number:1-877-240-9479
About the Study
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Conditions
Ovarian Cancer
Breast Cancer
Pancreatic Cancer
Prostate Cancer
Additional Indications Below for Module 4 and 5
Non-small Cell Lung Cancer
Colorectal Cancer
Bladder Cancer
Gastric Cancer
Biliary Cancer
Cervical Cancer
Endometrial Cancer
DRUG: AZD5305|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: T- Dxd|DRUG: Dato-DXd|DRUG: Camizestrant
Small Cell Lung Cancer Only in Module 5
Inclusion/Exclusion Criteria?
Primary, Secondary, Other Outcome Measures??
Locations in Canada
Kelowna General Hospital, Kelowna, British Columbia, V1Y 5L3, Canada
Vancouver General Hospital, Vancouver, British Columbia, V5Z 1K1, Canada
London Health Sciences Centre, London, Ontario, N6A 4L6, Canada
Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada
Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada
CHUM, Montréal, Québec, H2X 0A9, Canada
Jewish General Hospital, Montréal, Québec, H3T 1E2, Canada
Hôtel-Dieu de Québec, Québec, G1R 2J6, Canada
About the Study
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Conditions
Ovarian Cancer
Breast Cancer
Pancreatic Cancer
Prostate Cancer
Additional Indications Below for Module 4 and 5
Non-small Cell Lung Cancer
Colorectal Cancer
Bladder Cancer
Gastric Cancer
Biliary Cancer
Cervical Cancer
Endometrial Cancer
DRUG: AZD5305|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: T- Dxd|DRUG: Dato-DXd|DRUG: Camizestrant
Small Cell Lung Cancer Only in Module 5
Interventions
DRUG:
AZD5305
Paclitaxel
Carboplatin
T- Dxd
Dato-DXd
Camizestrant
Locations in Canada
Kelowna General Hospital, Kelowna, British Columbia, V1Y 5L3, Canada
Vancouver General Hospital, Vancouver, British Columbia, V5Z 1K1, Canada
London Health Sciences Centre, London, Ontario, N6A 4L6, Canada
Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada
Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada
CHUM, Montréal, Québec, H2X 0A9, Canada
Jewish General Hospital, Montréal, Québec, H3T 1E2, Canada
Hôtel-Dieu de Québec, Québec, G1R 2J6, Canada